Supplementary Figure S1 from Immune Marker Spatial Distribution and Clinical Outcome after PD-1 Blockade in Mismatch Repair–deficient, Advanced Colorectal Carcinomas

Supplementary Figure S1. PD-L1 (green) was expressed in (A) CD3+ T lymphocytes (magenta/pink), (B) CD68+ macrophages (red), panCK+ (cyan/light blue) tumor cells, and (C) tumor cells (red). PD-1 expression on CD8+ T lymphocytes was also observed.</p

Supplementary Table S1 from Immune Marker Spatial Distribution and Clinical Outcome after PD-1 Blockade in Mismatch Repair–deficient, Advanced Colorectal Carcinomas

Supplementary Table S1. Significant features in the univariable analysis for prediction of progression-free survival.</p

Supplementary Table S2 from Immune Marker Spatial Distribution and Clinical Outcome after PD-1 Blockade in Mismatch Repair–deficient, Advanced Colorectal Carcinomas

Supplementary Table S2. Significant features in the univariable analysis for prediction of tumor response.</p

Supplemental Figure 2 from Transcriptomic Signatures of MSI-High Metastatic Colorectal Cancer Predict Efficacy of Immune Checkpoint Inhibitors

Kaplan Meier curves for progression-free survival according to the unsupervised clusters and the line of immune checkpoint inhibitor</p

Supplemental Figure 3 from Transcriptomic Signatures of MSI-High Metastatic Colorectal Cancer Predict Efficacy of Immune Checkpoint Inhibitors

Tumor mutational burden and diagnosed Lynch syndrome in patients with MSI-high status determined by only one method</p

Supplemental Figure 4 from Transcriptomic Signatures of MSI-High Metastatic Colorectal Cancer Predict Efficacy of Immune Checkpoint Inhibitors

Heatmap with unsupervised clustering in the validation cohort</p